Dynaris
We set new standard in oxygen therapy; 7 patents, FDA, superior therapy, & more
Last Funded November 2021
$179,980
raised from 43 investors
Pitch Video
Investor Panel
Highlights
1
FDA 510 (K), EUA, ISO-13485 Quality System, FDA registered manufacturing in-house, Ready to go!
2
5.9 million patients on oxygen in the U.S. alone growing to over 7 million patients in 2023.
3
Protected by 7 U.S. Patents, more pending, foreign patents pending.
4
Experienced team with a history of success, from concept through acquisition. CEO has 28 patents
Our Team
The founders have been face-to-face with patients in the respiratory business for more than the last 4 decades. We've seen their pain and suffering. We have seized the opportunity to greatly help them and set a new standard in oxygen therapy. Quite simply, patients ask us to help them. They're family!